

Candela® Announces The Commercial Availability Of The Vbeam® Prima™ Laser System In Canada

Français

The new Vbeam Prima laser system takes Candela's "gold standard" 595 nm Pulsed Dye Laser (PDL) to the next level

WAYLAND, Mass., April 8, 2019 /CNW/ -- Candela Corporation, a leading global medical aesthetic device company, announces the introduction of the Vbeam® Prima™ laser system in Canada, representing the latest innovation in 30 years of clinical leadership for the Vbeam pulsed dye laser (PDL) franchise. The Vbeam Prima has an advanced 595 nm pulsed dye laser, a 1064 nm wavelength, two dermal cooling options and a number of other enhancements advancing pulsed dye applications. The Vbeam Prima device is the go-to laser for vascular conditions and effectively treats a broad range of skin conditions, including rosacea, port wine stains, acne, leg veins, spider veins, scars, benign pigmented lesions, wrinkles, warts, stretch marks and photo aging. The Vbeam Prima laser system was cleared by Health Canada and is now commercially available.

"The introduction of the Vbeam Prima laser system demonstrates Candela's commitment to trusted scientific technology, breakthrough innovation and proven clinical results," said Geoffrey Crouse, Chief Executive Officer of Candela. "Through extensive system performance testing in a number of clinics treating hundreds of patients, the Vbeam Prima device meets the highest performance and quality standards."

The Vbeam laser has been long considered the "gold standard" for the device-based treatment of rosacea and has been successfully used for the treatment of port wine stains and vascular anomalies in both adults and infants. The new Vbeam Prima laser system builds on this legacy of success with advanced features that offer an improved treatment experience and help physicians and their patients achieve better results.

"Through the rigorous testing that has been conducted, the Vbeam Prima laser system offers new innovation and clinically-proven breakthrough technology that has further increased patient satisfaction and will have a great impact on their overall quality of life," stated Dr. Sheetal Sapra of ICLS Dermatology & Plastic Surgery in Oakville, Ontario.

"Whether the patient concern is rosacea, port wine stains, facial and spider veins, or scars, the Vbeam Prima laser has taken the technology to the next level, offering more versatility and increased capabilities."

In a recent clinical study, the Vbeam Prima laser system was analyzed for the treatment of facial redness and rosacea symptoms, which were significantly reduced from moderate to mild after four treatments¹. Additionally, the Vbeam Prima device was tested for Poikiloderma of Civatte, with an average improvement of 49 percent after four treatment sessions².

"The Vbeam Perfecta laser has been one of the most popular devices in our practice due to its unparalleled record of proven results in conjunction with its wide range of clinical applications. Now with the launch of the new Vbeam Prima laser system, we can provide our patients with even faster, more efficient treatments," said Dr. B. Kent Remington, Board Certified Dermatologist at Remington Laser Dermatology Centre in Calgary, Canada. "I am extremely excited about the advancements provided by the new Prima, especially the 50% greater power enabling a 15 mm spot size, both contact and cryogen cooling, once-daily calibration³, and extended dye life thanks to a completely re-designed system," added Dr. Todd K. Remington, Board Certified Dermatologist at Remington Laser Dermatology Centre in Calgary, Canada.

The Vbeam Prima laser system will be available for in-office treatments by a licensed medical professional. For more information about the Vbeam Prima device, please visit <https://candelamedical.com/na>

Candela®

Candela is a leading global medical aesthetic device company with an extensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical aesthetic applications including hair removal, wrinkle reduction, tattoo removal, women's health treatments, facial resurfacing, traumatic and surgical scar treatments, body contouring, improving the skin's appearance through the treatment of benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Candela has a wide portfolio of trusted, leading products, including Vbeam®, the Gentle Family®, CO₂RE®, CO₂RE Intima®, Profound®, eIos Plus®, PicoWay®, UltraShape®, VelaShape®, Nordlys®, and other laser-based platforms. Acquired by Apax Partners in July 2017, the Company markets, services and supports its products in 86 countries. It has offices in the United States, Australia, Canada, China, France, Germany, Hong Kong, Israel, Italy, Japan, Korea, Portugal, Spain and the United Kingdom and many international distributors.

Media Contact:

EvolveMKD

P: 646.517.4220 | E: candela@evolvemkd.com

¹ Bernstein EF, Schomacker K, Paranjape A, Jones CJ. Pulsed dye laser treatment of rosacea using a novel 15mm spot size

² Bernstein EF, Schomacker K, Paranjape A, Jones CJ. Pulsed dye laser treatment of poikiloderma of Civatte using a novel 15mm spot size

³ Auto calibration upon first use

SOURCE Candela Corporation

Related Links

<http://www.candelamedical.com/na>